Therefore, the biochemical association between dysregulation of isoprenoid biosynthesis and AD suggests that reducing the P-Tau burden in the AD brain by inhibiting either hFPPS or hGGPPS may decelerate (or stop) the progression of this disease. The gene discussed is MAPT; the disease is Alzheimer disease.